Less than one in 10 individuals that would benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its inaugural recommendations on the drugs.
With more than one billion people worldwide currently living with obesity, it is advocating for increased and just availability to these injectable treatments.
According to estimates, over two billion could be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a lifelong illness that can be addressed with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key barriers to widespread access to the treatments that can help people shift considerable weight, notes the organization.
Skinny Jab Supply Crisis
Despite the current best projected case, the supply of such drugs would only suffice for about 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline calls on nations and manufacturers to expand access, through measures like licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so people reduce food intake.
People usually start to lose weight after several weeks of beginning the regular doses.
Studies indicates people may regain a significant portion within a year of stopping the medication, because their normal hunger resume.
To be above a healthy weight raises your risk for developing health problems, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity impacts individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.
